Dr. Bristow
Christopher Graybill Joins ARCA as Vice President, Clinical Development
05 mai 2021 16h05 HE | ARCA biopharma, Inc.
WESTMINSTER, Colo., May 05, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
Dr. Bristow
ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer
03 mai 2021 16h30 HE | ARCA biopharma, Inc.
WESTMINSTER, Colo., May 03, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
Dr. Bristow
ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update
18 mars 2021 16h30 HE | ARCA biopharma, Inc.
Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the third quarter of 2021 New patent issued by USPTO for use of Gencaro in treating...
Dr. Bristow
ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19
15 déc. 2020 08h30 HE | ARCA biopharma, Inc.
rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccinesrNAPc2 is the only novel compound being developed for COVID-19...
ARCA Logo - JPEG.jpg
ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders
09 déc. 2020 17h40 HE | ARCA biopharma, Inc.
WESTMINSTER, Colo., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that its 2020 Annual Meeting of Stockholders, scheduled for Thursday, December 10, 2020 at...
Dr. Bristow
AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation
23 nov. 2020 08h30 HE | ARCA biopharma, Inc.
Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or notAB201 is the only novel compound being developed for COVID Associated...
Dr. Bristow
ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update
02 nov. 2020 08h30 HE | ARCA biopharma, Inc.
Initiation of Phase 2b clinical trial evaluating AB201 as a potential treatment for COVID19 anticipated in fourth quarterTopline data from trial anticipated Q2 2021 WESTMINSTER, Colo., Nov. 02,...
Dr. Bristow
ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19
07 oct. 2020 08h30 HE | ARCA biopharma, Inc.
Initiation of Phase 2b clinical trial anticipated in Q4 2020Trial to enroll approximately 100 patients hospitalized with COVID-19Topline data anticipated Q2 2021 WESTMINSTER, Colo., Oct. 07, 2020 ...
ARCA Logo - JPEG.jpg
ARCA biopharma Announces Promotion of Chief Medical Officer and Vice President, Regulatory Affairs & Quality
05 oct. 2020 16h30 HE | ARCA biopharma, Inc.
WESTMINSTER, Colo., Oct. 05, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
Dr. Bristow
ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19
21 sept. 2020 08h00 HE | ARCA biopharma, Inc.
WESTMINSTER, Colo., Sept. 21, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...